昂科斯塔丁M诱导IFITM1表达以通过JAK-STAT信号来抑制乙型肝炎病毒复制
Yuchen Ye1, Ya Fu2, Caorui Lin2
1Department of Laboratory Medicine, Gene Diagnosis Research Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China; Clinical Laboratory Diagnostics, The First Clinical College, Fujian Medical University, Fuzhou, China.
Cellular and molecular gastroenterology and hepatology
|October 25, 2023
概括
哥斯塔丁M (OSM) 通过重塑免疫反应,有效抑制乙型肝炎病毒 (HBV) 复制. 这种细胞因子显示为慢性乙型肝炎 (CHB) 感染的新疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 慢性乙型肝炎 (CHB) 的有限功能治愈率需要新的治疗策略.
- 目前的治疗方法,如核酸类似物和干扰素,有效性有限.
- 开发新疗法以提高CHB患者的功能治愈率至关重要.
研究的目的:
- 为了研究抗肝炎B病毒 (HBV) 的潜力,interleukin-6家族的细胞因子.
- 确定最强大的细胞因子并阐明其对HBV的作用机制.
- 评估安哥斯塔丁M (OSM) 作为CHB的治疗候选药物.
主要方法:
- 使用HBV感染细胞查interleukin-6家族细胞因子.
- 在CHB患者中通过ELISA量化 Kostatin M (OSM) 水平.
- 使用RNA测序和在HBV感染小鼠中的体内研究来探索机制.
主要成果:
- 哥斯塔丁M (OSM) 显著抑制了HBV复制 (HBsAg,HBeAg,HBV DNA).
- 在CHB患者中,较高的OSM水平与较低的病毒标志物相关.
- OSM激活了JAK-STAT通路,诱导了抗病毒基因表达,包括干素诱导的跨膜蛋白1.
结论:
- 哥斯塔丁M (OSM) 通过调节免疫反应,表现出强大的抗HBV活性.
- OSM显示出作为慢性乙型肝炎 (CHB) 的治疗剂的潜力.
- 进一步开发OSM用于CHB治疗是有必要的.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
Eukaryotic Transcription Inhibitors
9.8K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.8K
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K


